newsfilter
← Latest News
GlobeNewswire·

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Praxis Precision Medicines granted restricted stock unit awards covering 2,754 common shares to 13 new non-executive employees on June 1, 2026.
  • The awards were issued under the 2024 Inducement Plan as inducements material to employment in compliance with Nasdaq Listing Rule 5635(c)(4).
  • The 2024 Inducement Plan is reserved exclusively for equity grants to individuals who were not previously employed by Praxis or returned after a bona fide period of non-employment.
  • The restricted stock units vest in four equal annual installments contingent on the employees' continued employment with Praxis on each vesting date.
  • Praxis is a CNS precision neuroscience biopharmaceutical company developing therapies for neuronal excitation-inhibition imbalance using its Cerebrum™ & Solidus™ platforms.